ArticlebioRxiv : the preprint server for biology2026
Pep2Mol: 3D Molecule Generation Targeting Protein-Protein Interfaces with Diffusion Models.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Protein-protein interactions (PPIs) are central to biological processes. Designing small molecules that modulate dysregulated PPIs holds strong promise for targeting undruggable proteins. However, existing structure-based drug design approaches focus on well-defined small-molecule binding pockets and struggle to generalize to large, shallow, and chemically complex PPI interfaces. Here, we introduce Pep2Mol, a diffusion-based generative model for 3D molecule design that targets orthosteric PPI sites by explicitly incorporating binding peptides or proteins as structural guidance, moving beyond conventional pocket-conditioned generation. To enable model development and benchmarking, we curate a large-scale, high-quality dataset of 10,956 experimentally resolved protein complex structure pairs, each pairing an orthosteric competitive ligand with a protein binder at overlapping receptor interfaces. Pep2Mol integrates two SE(3)-equivariant graph neural networks that encode protein-ligand and protein-peptide interactions respectively, and fuses these representations via attention-based conditioning to jointly guide the diffusion trajectory. Extensive evaluations demonstrate that Pep2Mol generates chemically valid ligands with state-of-the-art binding affinities, providing a strong foundation for small-molecule inhibitor design against challenging PPI interfaces.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.